Antibody-Drug Conjugates The 21st Century Magic Bullets for Cancer /
This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the f...
| Συγγραφή απο Οργανισμό/Αρχή: | |
|---|---|
| Άλλοι συγγραφείς: | , , |
| Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
| Γλώσσα: | English |
| Έκδοση: |
Cham :
Springer International Publishing : Imprint: Springer,
2015.
|
| Σειρά: | AAPS Advances in the Pharmaceutical Sciences Series,
17 |
| Θέματα: | |
| Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- 1 Antibody-Drug Conjugates: A Historical Review
- 2 Payloads of Antibody-Drug Conjugates
- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy
- 4 Linker Design for Antibody-Drug Conjugates
- 5 Formulation Development for Antibody-Drug Conjugates
- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates
- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates
- 8 Regulatory Considerations
- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy
- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal
- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate
- 12 Ado-Trastuzumab Emtansine
- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer
- 14 Summary and Future Directions.
